Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.025 (1.96%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

10 Jan 2012 13:18

RNS Number : 3113V
Epistem Holdings plc
10 January 2012
 



Company Epistem Plc

TIDM EHP.L (AIM)

Headline Directors' Shareholdings

Released 10th January 2012

Number

 

 

 Epistem Holdings Plc ("Epistem" or the "Company")

 

Directors' Shareholdings & AGM

 

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009

 

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 297 ordinary shares of 1.5p each. These shares were acquired on 2 November 2011, 9 November 2011 and 23 December 2011 at prices of 383p, 383pand 358p respectively.

Following these transactions, the current beneficial interests of the executive Directors are set out below:

 

Matthew Walls 8,965 (0.10%)

Dr Catherine Booth 983,320 (11.12%)

Dr Jeffrey Moore 15,645 (0.18%)

John Rylands 193,218 (2.18%)

 

Epistem further announces that all resolutions proposed at the Annual General Meeting held on 14 December 2011 were passed.

 

 

For further details please contact:

 

Epistem Plc

Matthew Walls, CEO +44 161 606 7258

John Rylands, Finance Director +44 161 606 7244

 

Peel Hunt LLP

James Steel / Vijay Barathan +44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBXGDBIBBBGDG
Date   Source Headline
24th Jun 202411:12 amRNSHolding(s) in Company
24th Jun 202411:11 amRNSHolding(s) in Company
17th Jun 20244:41 pmRNSHolding(s) in Company
13th Jun 20243:22 pmRNSHolding(s) in Company
11th Jun 202412:54 pmRNSHolding(s) in Company
7th Jun 202411:00 amRNSHolding(s) in Company
5th Jun 20243:45 pmRNSHolding(s) in Company
5th Jun 202411:39 amRNSHolding(s) in Company
31st May 20243:56 pmRNSBlock listing returns
31st May 202411:24 amRNSResult of General Meeting
30th May 20247:00 amRNSResult of Open Offer and REX Offer
24th May 20247:00 amRNSInitial orders of the Genedrive MT-RNR1 Products
21st May 202411:00 amRNSKey CYP2C19-ID test performance milestone achieved
15th May 20247:00 amRNSAmendment to Open Offer timetable
14th May 20247:00 amRNSPublication of Circular and Notice of GM
10th May 20247:00 amRNSCompletion of placing
9th May 20244:49 pmRNSProposed REX Retail Offer
9th May 20244:48 pmRNSProposed Fundraise for a minimum of £6.0 million
24th Apr 20243:36 pmRNSClinical Trial Agreement
3rd Apr 20245:00 pmRNSApplication for Listing & Total Voting Rights
3rd Apr 20247:00 amRNSNICE recommends the Genedrive CYP2C19-ID Kit
28th Mar 20247:00 amRNSHalf-year Report
26th Mar 20247:00 amRNSInvestor presentation
19th Mar 20243:53 pmRNSApplication for Listing & Total Voting Rights
15th Mar 202412:30 pmRNSReceipt of R&D tax credit
19th Feb 20247:00 amRNSNICE Early Value Assessment update
6th Feb 20242:03 pmRNSDirector/PDMR Shareholding
2nd Feb 20243:35 pmRNSTotal Voting Rights
19th Jan 20244:14 pmRNSTotal Voting Rights
15th Jan 20243:21 pmRNSTotal Voting Rights
10th Jan 20247:00 amRNSTotal Voting Rights
2nd Jan 20247:00 amRNSEquity Prepayment Facility drawdown
29th Dec 202311:44 amRNSResult of AGM
20th Dec 20234:57 pmRNSTotal Voting Rights
20th Dec 20237:00 amRNSInitial overseas orders of MT-RNR1 ID kit
7th Dec 20237:00 amRNSTotal Voting Rights
6th Dec 20237:00 amRNSPosting of annual report and notice of AGM
6th Dec 20237:00 amRNSTotal Voting Rights
4th Dec 20231:13 pmRNSMT-RNR1 ID kit adopted for routine use in Brighton
30th Nov 20235:29 pmRNSBlock listing Interim Review
30th Nov 20237:00 amRNSFinal Results
29th Nov 20235:25 pmRNSEquity Prepayment Facility drawdown
16th Nov 20237:00 amRNSNotice of Results
20th Oct 202310:52 amRNSTotal Voting Rights
28th Sep 202312:35 pmRNSc£1.2m grant awarded
21st Sep 20232:39 pmRNSApplication for listing & total voting rights
11th Sep 20232:17 pmRNSBoard changes
6th Sep 20237:00 amRNSUKCA marking achieved for new CYP2C19 test
4th Aug 20234:00 pmRNSTotal Voting Rights
5th Jul 20239:11 amRNSEquity Prepayment Facility drawdown

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.